Autocrine VEGF loops, signaling pathways, and acute leukemia regulation

References

• Leung D W, Cachianes G, Kuang W J, Goeddel D V, Ferrara N. Vascular endothelial growth factor is a secreted angiogenic mitogen. Science 1989; 246: 1306–1309
   PubMed Web of Science ®Google Scholar
• Perez-Atayde A R, Sallan S E, Tedrow U, Connors S, Allred E, Folkman J. Spectrum of tumor angiogenesis in the bone marrow of children with acute lymphoblastic leukemia. Am J Pathol 1997; 150: 815–821
   PubMed Web of Science ®Google Scholar
• Yetgin S, Yenicesu I, Cetin M, Tuncer M. Clinical importance of serum vascular endothelial and basic fibroblast growth factors in children with acute lymphoblastic leukemia. Leuk Lymphoma 2001; 42: 83–88
   PubMed Web of Science ®Google Scholar
• Hanahan D, Folkman J. Patterns and emerging mechanisms of the angiogenic switch during tumorigenesis. Cell 1996; 86: 353–364
   PubMed Web of Science ®Google Scholar
• Fiedler W, Graeven U, Ergun S, Verago S, Kilic N, Stockschlader M, et al. Vascular endothelial growth factor, a possible paracrine growth factor in human acute myeloid leukemia. Blood 1997; 89: 1870–1875
   PubMed Web of Science ®Google Scholar
• Aguayo A, Estey E, Kantarjian H, Mansouri T, Gidel C, Keating M, et al. Cellular vascular endothelial growth factor is a predictor of outcome in patients with acute myeloid leukemia. Blood 1999; 94: 3717–3721
   PubMed Web of Science ®Google Scholar
• Aguayo A, Kantarjian H, Manshouri T, Gidel C, Estey E, Thomas D, et al. Angiogenesis in acute and chronic leukemias and myelodysplastic syndromes. Blood 2000; 96: 2240–2245
   PubMed Web of Science ®Google Scholar
• Padro T, Ruiz S, Bieker R, Burger H, Steins M, Kienast J, et al. Increased angiogenesis in the bone marrow of patients with acute myeloid leukemia. Blood 2000; 95: 2637–2644
   PubMed Web of Science ®Google Scholar
• Hussong J W, Rodgers G M, Shami P J. Evidence of increased angiogenesis in patients with acute myeloid leukemia. Blood 2000; 95: 309–313
   PubMed Web of Science ®Google Scholar
• de Bont E S, Rosati S, Jacobs S, Kamps W A, Vellenga E. Increased bone marrow vascularization in patients with acute myeloid leukaemia: a possible role for vascular endothelial growth factor. Br J Haematol 2001; 113: 296–304
   PubMed Web of Science ®Google Scholar
• Ghannadan M, Wimazal F, Simonitsch I, Sperr W R, Mayerhofer M, Sillaber C, et al. Immunohistochemical detection of VEGF in the bone marrow of patients with acute myeloid leukemia. Correlation between VEGF expression and the FAB category. Am J Clin Pathol 2003; 119: 663–671
   PubMed Web of Science ®Google Scholar
• Brunner B, Gunsilius E, Schumacher P, Zwierzina H, Gastl G, Stauder R. Blood levels of angiogenin and vascular endothelial growth factor are elevated in myelodysplastic syndromes and in acute myeloid leukemia. J Hematother Stem Cell Res 2002; 11: 119–125
   PubMedGoogle Scholar
• Lundberg L G, Lerner R, Sundelin P, Rogers R, Folkman J, Palmblad J. Bone marrow in polycythemia vera, chronic myelocytic leukemia, and myelofibrosis has an increased vascularity. Am J Pathol 2000; 157: 15–19
   PubMed Web of Science ®Google Scholar
• Verstovsek S, Lunin S, Kantarjian H, Manshouri T, Faderl S, Cortes J, et al. Clinical relevance of VEGF receptors 1 and 2 in patients with chronic myelogenous leukemia. Leuk Res 2003; 27: 661–669
   PubMed Web of Science ®Google Scholar
• Chen H, Treweeke A T, West D C, Till K J, Cawley J C, Zuzel M, et al. In vitro and in vivo production of vascular endothelial growth factor by chronic lymphocytic leukemia cells. Blood 2000; 96: 3181–3187
   PubMed Web of Science ®Google Scholar
• Koomagi R, Zintl F, Sauerbrey A, Volm M. Vascular endothelial growth factor in newly diagnosed and recurrent childhood acute lymphoblastic leukemia as measured by real-time quantitative polymerase chain reaction. Clin Cancer Res 2001; 7: 3381–3384
   PubMed Web of Science ®Google Scholar
• Hu Q, Dey A L, Yang Y, Shen Y, Jilani I B, Estey E H, et al. Soluble vascular endothelial growth factor receptor 1, and not receptor 2, is an independent prognostic factor in acute myeloid leukemia and myelodysplastic syndromes. Cancer 2004; 100: 1884–1891
   PubMed Web of Science ®Google Scholar
• Bellamy W T, Richter L, Frutiger Y, Grogan T M. Expression of vascular endothelial growth factor and its receptors in hematopoietic malignancies. Cancer Res 1999; 59: 728–733
   PubMed Web of Science ®Google Scholar
• Padro T, Bieker R, Ruiz S, Steins M, Retzlaff S, Burger H, et al. Overexpression of vascular endothelial growth factor (VEGF) and its cellular receptor KDR (VEGFR-2) in the bone marrow of patients with acute myeloid leukemia. Leukemia 2002; 16: 1302–1310
   PubMed Web of Science ®Google Scholar
• Dias S, Hattori K, Zhu Z, Heissig B, Choy M, Lane W, et al. Autocrine stimulation of VEGFR-2 activates human leukemic cell growth and migration. J Clin Invest 2000; 106: 511–521
   PubMed Web of Science ®Google Scholar
• Aguayo A, Kantarjian H M, Estey E H, Giles F J, Verstovsek S, Manshouri T, et al. Plasma vascular endothelial growth factor levels have prognostic significance in patients with acute myeloid leukemia but not in patients with myelodysplastic syndromes. Cancer 2002; 95: 1923–1930
   PubMed Web of Science ®Google Scholar
• de Bont E S, Fidler V, Meeuwsen T, Scherpen F, Hahlen K, Kamps W A. Vascular endothelial growth factor secretion is an independent prognostic factor for relapse-free survival in pediatric acute myeloid leukemia patients. Clin Cancer Res 2002; 8: 2856–2861
   PubMed Web of Science ®Google Scholar
• Faderl S, Do K A, Johnson M M, Keating M, O'Brien S, Jilani I, et al. Angiogenic factors may have a different prognostic role in adult acute lymphoblastic leukemia. Blood 2005; 106: 4303–4307
   PubMed Web of Science ®Google Scholar
• Molica S, Vacca A, Levato D, Merchionne F, Ribatti D. Angiogenesis in acute and chronic lymphocytic leukemia. Leuk Res 2004; 28: 321–324
   PubMed Web of Science ®Google Scholar
• Frankel A E, Gill P S. VEGF and myeloid leukemias. Leuk Res 2004; 28: 675–677
   PubMed Web of Science ®Google Scholar
• Aguayo A, Giles F, Albitar M. Vascularity, angiogenesis and angiogenic factors in leukemias and myelodysplastic syndromes. Leuk Lymphoma 2003; 44: 213–222
   PubMed Web of Science ®Google Scholar
• Liu P, Wang Y, Li Y H, Yang C, Zhou Y L, Li B, et al. Adenovirus-mediated gene therapy with an antiangiogenic fragment of thrombospondin-1 inhibits human leukemia xenograft growth in nude mice. Leuk Res 2003; 27: 701–708
   PubMed Web of Science ®Google Scholar
• Lai R, Estey E, Shen Y, Despa S, Kantarjian H, Beran M, et al. Clinical significance of plasma endostatin in acute myeloid leukemia/myelodysplastic syndrome. Cancer 2002; 94: 14–17
   PubMed Web of Science ®Google Scholar
• Shweiki D, Itin A, Soffer D, Keshet E. Vascular endothelial growth factor induced by hypoxia may mediate hypoxia-initiated angiogenesis. Nature 1992; 359: 843–845
   PubMed Web of Science ®Google Scholar
• Levy A P, Levy N S, Wegner S, Goldberg M A. Transcriptional regulation of the rat vascular endothelial growth factor gene by hypoxia. J Biol Chem 1995; 270: 13333–13340
   PubMed Web of Science ®Google Scholar
• Liu Y, Cox S R, Morita T, Kourembanas S. Hypoxia regulates vascular endothelial growth factor gene expression in endothelial cells. Identification of a 5’ enhancer. Circ Res 1995; 77: 638–643
   PubMed Web of Science ®Google Scholar
• Jiang B H, Agani F, Passaniti A, Semenza G L. V-SRC induces expression of hypoxia-inducible factor 1 (HIF-1) and transcription of genes encoding vascular endothelial growth factor and enolase 1: involvement of HIF-1 in tumor progression. Cancer Res 1997; 57: 5328–5335
   PubMed Web of Science ®Google Scholar
• Shi Q, Le X, Abbruzzese J L, Peng Z, Qian C N, Tang H, et al. Constitutive Sp1 activity is essential for differential constitutive expression of vascular endothelial growth factor in human pancreatic adenocarcinoma. Cancer Res 2001; 61: 4143–4154
   PubMed Web of Science ®Google Scholar
• Deroanne C F, Hajitou A, Calberg-Bacq C M, Nusgens B V, Lapiere C M. Angiogenesis by fibroblast growth factor 4 is mediated through an autocrine up-regulation of vascular endothelial growth factor expression. Cancer Res 1997; 57: 5590–5597
   PubMed Web of Science ®Google Scholar
• Ryuto M, Ono M, Izumi H, Yoshida S, Weich H A, Kohno K, et al. Induction of vascular endothelial growth factor by tumor necrosis factor alpha in human glioma cells. Possible roles of SP-1. J Biol Chem 1996; 271: 28220–28228
   PubMed Web of Science ®Google Scholar
• Pertovaara L, Kaipainen A, Mustonen T, Orpana A, Ferrara N, Saksela O, et al. Vascular endothelial growth factor is induced in response to transforming growth factor-β in fibroblastic and epithelial cells. J Biol Chem 1994; 269: 6271–6274
   PubMed Web of Science ®Google Scholar
• Goad D L, Rubin J, Wang H, Tashjian A H, Jr, Patterson C. Enhanced expression of vascular endothelial growth factor in human SaOS-2 osteoblast-like cells and murine osteoblasts induced by insulin-like growth factor I. Endocrinology 1996; 137: 2262–2268
   PubMed Web of Science ®Google Scholar
• Li J, Perrella M A, Tsai J C, Yet S F, Hsieh C M, Yoshizumi M, et al. Induction of vascular endothelial growth factor gene expression by interleukin-1β in rat aortic smooth muscle cells. J Biol Chem 1995; 270: 308–312
   PubMed Web of Science ®Google Scholar
• Cohen T, Nahari D, Cerem L W, Neufeld G, Levi B Z. Interleukin 6 induces the expression of vascular endothelial growth factor. J Biol Chem 1996; 271: 736–741
   PubMed Web of Science ®Google Scholar
• Matsumoto K, Ohi H, Kanmatsuse K. Interleukin 10 and interleukin 13 synergize to inhibit vascular permeability factor release by peripheral blood mononuclear cells from patients with lipoid nephrosis. Nephron 1997; 77: 212–218
   PubMedGoogle Scholar
• Siemeister G, Weindel K, Mohrs K, Barleon B, Martiny-Baron G, Marme D. Reversion of deregulated expression of vascular endothelial growth factor in human renal carcinoma cells by von Hippel-Lindau tumor suppressor protein. Cancer Res 1996; 56: 2299–2301
   PubMed Web of Science ®Google Scholar
• Van Meir E G, Polverini P J, Chazin V R, Su Huang H J, de Tribolet N, Cavenee W K. Release of an inhibitor of angiogenesis upon induction of wild type p53 expression in glioblastoma cells. Nat Genet 1994; 8: 171–176
   PubMed Web of Science ®Google Scholar
• Mukhopadhyay D, Knebelmann B, Cohen H T, Ananth S, Sukhatme V P. The von Hippel-Lindau tumor suppressor gene product interacts with Sp1 to repress vascular endothelial growth factor promoter activity. Mol Cell Biol 1997; 17: 5629–5639
   PubMed Web of Science ®Google Scholar
• Teodoro J G, Parker A E, Zhu X, Green M R. p53-Mediated inhibition of angiogenesis through up-regulation of a collagen prolyl hydroxylase. Science 2006; 313: 968–971
   PubMed Web of Science ®Google Scholar
• Scortegagna M, Morris M A, Oktay Y, Bennett M, Garcia J A. The HIF family member EPAS1/HIF-2α is required for normal hematopoiesis in mice. Blood 2003; 102: 1634–1640
   PubMed Web of Science ®Google Scholar
• Mortensen B T, Jensen P O, Helledie N, Iversen P O, Ralfkiaer E, Larsen J K, et al. Changing bone marrow micro-environment during development of acute myeloid leukaemia in rats. Br J Haematol 1998; 102: 458–464
   Google Scholar
• Wellmann S, Guschmann M, Griethe W, Eckert C, von Stackelberg A, Lottaz C, et al. Activation of the HIF pathway in childhood ALL, prognostic implications of VEGF. Leukemia 2004; 18: 926–933
   PubMed Web of Science ®Google Scholar
• Mayerhofer M, Valent P, Sperr W R, Griffin J D, Sillaber C. BCR/ABL induces expression of vascular endothelial growth factor and its transcriptional activator, hypoxia inducible factor-1α, through a pathway involving phosphoinositide 3-kinase and the mammalian target of rapamycin. Blood 2002; 100: 3767–3775
   PubMed Web of Science ®Google Scholar
• Narendran A, Ganjavi H, Morson N, Connor A, Barlow J W, Keystone E, et al. Mutant p53 in bone marrow stromal cells increases VEGF expression and supports leukemia cell growth. Exp Hematol 2003; 31: 693–701
   PubMed Web of Science ®Google Scholar
• Dias S, Choy M, Alitalo K, Rafii S. Vascular endothelial growth factor (VEGF)-C signaling through FLT-4 (VEGFR-3) mediates leukemic cell proliferation, survival, and resistance to chemotherapy. Blood 2002; 99: 2179–2184
   PubMed Web of Science ®Google Scholar
• Bellamy W T. Expression of vascular endothelial growth factor and its receptors in multiple myeloma and other hematopoietic malignancies. Semin Oncol 2001; 28: 551–559
   PubMed Web of Science ®Google Scholar
• Allouche M, Bayard F, Clamens S, Fillola G, Sie P, Amalric F. Expression of basic fibroblast growth factor (bFGF) and FGF-receptors in human leukemic cells. Leukemia 1995; 9: 77–86
   PubMed Web of Science ®Google Scholar
• Katoh O, Takahashi T, Oguri T, Kuramoto K, Mihara K, Kobayashi M, et al. Vascular endothelial growth factor inhibits apoptotic death in hematopoietic cells after exposure to chemotherapeutic drugs by inducing MCL1 acting as an antiapoptotic factor. Cancer Res 1998; 58: 5565–5569
   PubMed Web of Science ®Google Scholar
• Gerber H P, Malik A K, Solar G P, Sherman D, Liang X H, Meng G, et al. VEGF regulates haematopoietic stem cell survival by an internal autocrine loop mechanism. Nature 2002; 417: 954–958
   PubMed Web of Science ®Google Scholar
• Santos S C, Dias S. Internal and external autocrine VEGF/KDR loops regulate survival of subsets of acute leukemia through distinct signaling pathways. Blood 2004; 103: 3883–3889
   PubMed Web of Science ®Google Scholar
• Dias S, Shmelkov S V, Lam G, Rafii S. VEGF(165) promotes survival of leukemic cells by Hsp90-mediated induction of Bcl-2 expression and apoptosis inhibition. Blood 2002; 99: 2532–2540
   PubMed Web of Science ®Google Scholar
• Wang L, Chen L, Benincosa J, Fortney J, Gibson L F. VEGF-induced phosphorylation of Bcl-2 influences B lineage leukemic cell response to apoptotic stimuli. Leukemia 2005; 19: 344–353
   PubMed Web of Science ®Google Scholar
• List A F, Glinsmann-Gibson B, Stadheim C, Meuillet E J, Bellamy W, Powis G. Vascular endothelial growth factor receptor-1 and receptor-2 initiate a phosphatidylinositide 3-kinase-dependent clonogenic response in acute myeloid leukemia cells. Exp Hematol 2004; 32: 526–535
   PubMed Web of Science ®Google Scholar
• Fragoso R, Pereira T, Wu Y, Zhu Z, Cabecadas J, Dias S. VEGFR-1 (FLT-1) activation modulates acute lymphoblastic leukemia localization and survival within the bone marrow, determining the onset of extramedullary disease. Blood 2006; 107: 1608–1616
   PubMed Web of Science ®Google Scholar
• Dias S, Hattori K, Heissig B, Zhu Z, Wu Y, Witte L, et al. Inhibition of both paracrine and autocrine VEGF/ VEGFR-2 signaling pathways is essential to induce long-term remission of xenotransplanted human leukemias. Proc Natl Acad Sci USA 2001; 98: 10857–10862
   PubMed Web of Science ®Google Scholar
• Zhang H, Li Y, Li H, Bassi R, Jimenez X, Witte L, et al. Inhibition of both the autocrine and the paracrine growth of human leukemia with a fully human antibody directed against vascular endothelial growth factor receptor 2. Leuk Lymphoma 2004; 45: 1887–1897
   PubMed Web of Science ®Google Scholar
• Hanahan D, Bergers G, Bergsland E. Less is more, regularly: metronomic dosing of cytotoxic drugs can target tumor angiogenesis in mice. J Clin Invest 2000; 105: 1045–1047
   PubMed Web of Science ®Google Scholar
• Bartlett J B, Dredge K, Dalgleish A G. The evolution of thalidomide and its IMiD derivatives as anticancer agents. Nat Rev Cancer 2004; 4: 314–322
   PubMed Web of Science ®Google Scholar
• Hayashi T, Hideshima T, Anderson K C. Novel therapies for multiple myeloma. Br J Haematol 2003; 120: 10–17
   PubMed Web of Science ®Google Scholar
• Steins M B, Padro T, Bieker R, Ruiz S, Kropff M, Kienast J, et al. Efficacy and safety of thalidomide in patients with acute myeloid leukemia. Blood 2002; 99: 834–839
   PubMed Web of Science ®Google Scholar
• Thomas D A, Estey E, Giles F J, Faderl S, Cortes J, Keating M, et al. Single agent thalidomide in patients with relapsed or refractory acute myeloid leukaemia. Br J Haematol 2003; 123: 436–441
   PubMed Web of Science ®Google Scholar
• Roboz G J, Dias S, Lam G, Lane W J, Soignet S L, Warrell R P, Jr, et al. Arsenic trioxide induces dose- and time-dependent apoptosis of endothelium and may exert an antileukemic effect via inhibition of angiogenesis. Blood 2000; 96: 1525–1530
   PubMed Web of Science ®Google Scholar
• Park M J, Park I C, Bae I J, Seo K M, Lee S H, Hong S I, et al. Tetraarsenic oxide, a novel orally administrable angiogenesis inhibitor. Int J Oncol 2003; 22: 1271–1276
   PubMed Web of Science ®Google Scholar
• Kini A R, Peterson L A, Tallman M S, Lingen M W. Angiogenesis in acute promyelocytic leukemia: induction by vascular endothelial growth factor and inhibition by all-trans retinoic acid. Blood 2001; 97: 3919–3924
   PubMed Web of Science ®Google Scholar
• Fiedler W, Mesters R, Tinnefeld H, Loges S, Staib P, Duhrsen U, et al. A phase 2 clinical study of SU5416 in patients with refractory acute myeloid leukemia. Blood 2003; 102: 2763–2767
   PubMed Web of Science ®Google Scholar
• Giles F J, Cooper M A, Silverman L, Karp J E, Lancet J E, Zangari M, et al. Phase II study of SU5416 – a small-molecule, vascular endothelial growth factor tyrosine-kinase receptor inhibitor – in patients with refractory myeloproliferative diseases. Cancer 2003; 97: 1920–1928
   PubMed Web of Science ®Google Scholar
• Giles F J, Stopeck A T, Silverman L R, Lancet J E, Cooper M A, Hannah A L, et al. SU5416, a small molecule tyrosine kinase receptor inhibitor, has biologic activity in patients with refractory acute myeloid leukemia or myelodysplastic syndromes. Blood 2003; 102: 795–801
   PubMed Web of Science ®Google Scholar